arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Axogen, Inc.

AXGN
$43.30 ▼ -1.24 (-2.78%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
33
Health
Poor
Bearish
auto_awesome

Analytical Summary

Axogen, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.0B
Dividend Yield —
Revenue Growth 20.2% ↗
Op. Margin -3.5% ↘
ROIC -3.5% ↘
FCF / Share $-0.06 ↘
Trailing P/E —
Price / Book 15.9x
FCF Yield —
Debt / Equity 0.38
info Valuation on last close. End-of-day price, Sep 23, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$225.21M
↑ +20.2% —
Net Income Profit after all expenses
$-15.70M
↓ -57.6% —
Operating Margin Operating profit as % of sales
-3.5%
↓ -98.6% 22th
FCF / Share Free cash flow per share
$-0.06
↓ -296.6% —
Long-Term Debt Long-term obligations
$48.39M
↑ +1.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
21
Returns ↑
33
Financial Health →
51
Cash Quality ↓
29

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 66 quarters